

**Lab Central Tour  
October 9, 2018  
Attendee Biographies**

**Hosted by:**

**Mark Chance, Vice Dean for Research, CWRU School of Medicine**

Dr. Mark Chance is an internationally recognized expert in proteomics and structural biology with over 250 publications who has built multiple internationally recognized science and training programs over a 25-year career in academia. As Vice Dean for Research at the School of Medicine, he has reshaped the strategic directions of the Academic Medical Center in research and graduate education to respond to current trends in biomedical research. He has led an innovation and commercialization program to develop therapeutics, the Council to Advance Human Health. He serves as the Director of the Center for Proteomics and Bioinformatics and as one of the leads for the Clinical and Translational Science Collaborative, is a member of numerous advisory boards and frequently invited lecturer at national and international meetings. He has multiple patents and patent filings and has launched a successful startup company in the field of precision medicine, NeoProteomics, Inc..



**Tour Guide:**

**Luke Wallrich, Manager, Events and Operations, LabCentral**

Luke Wallrich is the events and operations manager at LabCentral. He is responsible for the planning and execution of events, seminars, lectures, and resident programming which facilitate community and sponsor engagement. For nearly 10 years, Luke has worked in event management and company operations. From founding his own company and revamping existing large scale festival events to production management and event facility operations, his experience is comprised of time spent at multiple levels of the business and hospitality industries. Luke has a background in music and holds a degree in Opera Performance from the University of Minnesota – Duluth.



### Honored Guests

#### **Jeff Epstein, Executive Director, MidTown Cleveland; Director, Health Tech Corridor**

Mr. Jeff Epstein comes to the Health-Tech Corridor from The Coral Company, where he served as Vice President of Development. Prior to joining Coral, Mr. Epstein participated in the Cleveland Executive Fellowship, a one-year civic leadership development program. He holds a J.D. from Georgetown University Law Center and an undergraduate degree in Public Policy Studies from Duke University. After graduating from Duke, Mr. Epstein worked for the management consulting firm A.T. Kearney and the political polling and marketing firm Penn Schoen Berland. Mr. Epstein serves on the executive board of the Cleveland Tenants Organization and the boards of Cleveland Housing Network and Congregation Shaarey Tikvah.



#### **Daniel Fischer, Founder, Tevard Biosciences; Program Director, Industry Liaison Program, MIT**

Mr. Daniel Fischer co-founded Tevard Biosciences to develop gene therapy approaches to cure Dravet Syndrome and other rare diseases. The team is currently working on several novel gene therapy centered platforms. Mr. Fischer also serves as a program director for the Industry Liaison Program at MIT, working on innovation management, support for start-up companies, and state of the art technology in several disciplines. Mr. Fischer previously founded and led Parent Powered Innovation, and Comerxia, and is currently on the board of the Anti-Defamation League.



#### **Deirdre Gannon, Vice President of Strategic Development, BioEnterprise**

Deirdre Gannon is the Vice President of Strategic Development for BioEnterprise. In this position, she leads the organization's strategic and community initiatives. Prior to joining BioEnterprise, Deirdre was the Director of Strategic Planning and the Corporate Innovation Incubator at GOJO Industries. In these roles, she pioneered growth initiatives, developed customer-driven products, and crafted actionable approaches to validating and implementing big ideas. With over 10 years of experience with both large and boutique management consulting firms, Deirdre has expertise in structured problem-solving, B-to-B market research, and change leadership. Deirdre earned an MBA from Weatherhead School of Management, Case Western Reserve University, a B.S. in Accountancy from Miami University, and was licensed as a Certified Public Accountant during her tenure at E&Y.



#### **David Geho, Head of Imaging, Vertex Pharmaceuticals, Inc.**

Dr. David Geho recently became head of Imaging for Vertex Pharmaceuticals, Inc. in addition to his role as head of translational biology. Dr. Geho is a board certified physician who specializes in research and development, in particular imaging and translational medicine. Previously, Dr. Geho worked as the senior lead for translational medicine-oncology for Roche, clinical project leader for GE and the director of Imaging for Merck. Dr. Geho received his MD and PhD from Case Western Reserve University, and did a medical staff fellowship and residency at the National Cancer Institute.

**Bob Hurwitz, BioMendics, LLC, Co-Founder of OfficeMax, Founding Owner of the Coral Company**

In 1987, Mr. Hurwitz co-founded OfficeMax, Inc., where he was founding Chairman and CEO, taking a leadership role in building it into a national chain of office supply superstores, which was subsequently sold to K-mart. Mr. Hurwitz is also a founding owner of The Coral Company, which over the last 24 years has grown into a full service real estate development, construction and management firm. In 1996, Mr. Hurwitz founded Homeplace, Inc. which ultimately grew into a national chain of 100 home furnishings superstores before going into reorganization and eventually being sold. Since 2001 Mr. Hurwitz has engaged in assisting other entrepreneurs in developing their ideas and businesses. He is an active member on the Jumpstart Board and is involved on the organization's strategic planning, compensation, human resources and finance committees.



**Warren Lammert, Founder, Principal, CIO of Granite Point Capital**

Mr. Lammert is founder, principal and chief investment officer of Granite Point Capital formed in January 2004 and has more than 18 years of investment industry experience. Prior to the formation of Granite Point Capital, he spent 14 years at Janus serving in investment and senior management roles. From July 1984 until joining Janus in 1987, Mr. Lammert served as research associate and then associate analyst at Fred Alger Management. He serves on the board of directors of Village Ventures, is a founder of The Epilepsy Project and Epilepsy.com, and has also earned the right to use the Chartered Financial Analyst designation. Mr. Lammert received his B.A. in economics from Yale University and graduated with Distinction from the London School of Economics with a M.Sc. in economic history.



**Harvey Lodish, Founder and Scientific Board Member, Genzyme, Millennium Pharmaceuticals, Rubius Pharmaceuticals. Professor of Biological Engineering, MIT; Founding Member, the Whitehead Institute**

Dr. Harvey Lodish, PhD is a Professor at MIT and the Whitehead Institute for Biomedical Research and serves on the Board of Trustees of Boston Children's Hospital and Chair of the Board Research Committee. Dr. Lodish was a founder and Scientific Advisory Board Member of Genzyme, Inc and Millennium Pharmaceuticals, Inc. In 2014 he founded Rubius Pharmaceuticals, which had a successful IPO in July 2018. Dr. Lodish is a Member of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences, and has served on advisory panels for the Cleveland Clinic, NIH, NSF, and American Cancer Society, and on the advisory boards of several other institutions. Dr. Lodish received his A.B. degree Summa Cum Laude and with Highest Honors in Chemistry and Mathematics, from Kenyon College, and his Ph.D. degree in genetics from the Rockefeller University.



**Tom McDonald, CEO and President, McDonald Partners**

Prior to founding McDonald Partners, Mr. McDonald served as president and CEO for Wayne Hummer Investments in Chicago, Illinois from 2003-2005. Prior to joining Wayne Hummer, Mr. McDonald spent 12 years with McDonald Investments in Cleveland, Ohio. In 1998, KeyBank bought McDonald Investments and Mr. McDonald was responsible for integrating the Private Bank and Private Client Group. He successfully integrated the organizations to fully deliver all aspects the combined wealth management firm had to offer. During his tenure at McDonald Investments, Mr. McDonald served on various committees including McDonald Investments' Board of Directors, the firm's Capital Commitment Committee and the Compliance Committee.



**Karen McGuire, CEO, BioMendics, LLC**

Dr. Karen McGuire is the CEO of BioMendics, LLC and works closely with the BioMendics team to ensure successful product development while providing substantial business opportunities to its investors. Dr. McGuire is a biomedical engineer with a doctorate in cellular & molecular biology and is focused on pharmacology and the development of natural products, proprietary molecules and liquid crystal biologics for cancer, orthopedics, wound care, metabolic and inflammatory diseases. She has authored and co-authored several publications and patents with several patents currently pending.



**Beno Michel, Clinical Consultant, Fluence Therapeutics; Scientific Advisor, BioMendics, Inc.**

Dr. Beno Michel, MD serves as clinical consultant of Fluence Therapeutics, Inc. and is a member of the scientific advisory board for BioMendics, Inc. In addition to a distinguished career as a dermatologist and a businessman, Dr. Michel founded several successful companies, served as Clinical Professor of Dermatology and Department Chair at Case Western Reserve University Medical School, served as President of the American Society of Dermatopathology, the Cleveland Dermatological Society and the Academy of Medicine of Cleveland and Northern Ohio. Dr. Michel graduated from the University Geneva and completed a fellowship in dermatology at the Mayo Clinic.



**Tony Panzica, President and CEO, Panzica Construction, Inc**

Mr. Tony Panzica is owner, president and chief executive officer of Panzica Construction Co. in Mayfield. Mr. Panzica is a former Board Chairman and current Board member of the Construction Employers Association. Tony Panzica earned a B.S. degree in civil engineering from Purdue University in 1975 and his professional engineering license shortly thereafter. Mr. Panzica has served on boards and committees of both non-profit and construction industry-related groups and taken on volunteer leadership roles at universities, churches, libraries, and arts organizations like the Cleveland Play House. He is currently serving on the Board of the Cleveland Play House.



**Megan Wilson, Chief of Staff, Cleveland Foundation**

Ms. Megan Wilson rejoined the Cleveland Foundation as chief of staff in April 2018 after working in operations with BioMotiv, the mission-driven company associated with The Harrington Project for Discovery & Development. Prior to joining BioMotiv, Ms. Wilson worked with the foundation on the donor relations team at the Cleveland Foundation. She served as a donor relations assistant providing support to the director of donor relations and the donor relations officers. Ms. Wilson received her master's degree in public administration from Cleveland State University and her bachelor's degree from Baldwin Wallace University, with a focus on business administration and art history.



**Investigators**

**Mitch Drumm, Professor, Pediatrics and Genetics and Genome Sciences**


Dr. Mitchell Drumm received his BS in genetics from The Ohio State University in 1983 and his PhD in Human Genetics from the University of Michigan in 1990. His doctoral degree work was carried out in the laboratory of Francis Collins, MD, PhD, with whom he was a co-discoverer of the gene that causes cystic fibrosis (CF). Dr. Drumm continues to work on CF and joined the faculty at Case Western Reserve University in 1992 and is a Professor in the Departments of Pediatrics and Genetics and Genome Sciences. He has authored over 80 peer-reviewed manuscripts and several book chapters on cystic fibrosis and holds three patents relevant to the disease as well. In 2007, Dr. Drumm was appointed Director of Basic Research of the Willard A.



Bernbaum Cystic Fibrosis Research Center and in 2011 Vice Chair for Research in the Department of Pediatrics. Dr. Drumm also serves as an advisor to several cystic fibrosis research centers, reviews grants applications for the National Institutes of Health and co-chairs the Research and Research Training Committee of the Cystic Fibrosis Foundation.

**John "Chip" Tilton, Associate Professor, Nutrition**

Dr. John "Chip" Tilton, associate professor in the Department of Nutrition at Case Western Reserve University School of Medicine, maintains a research focus on understanding what makes cells susceptible to viral infection, but has more recently shifted to repurposing viruses for intracellular delivery of therapeutic proteins. Dr. Tilton was a clinical research fellow at the National Institutes of Health and a senior research investigator at the University of Pennsylvania before starting his lab at Case Western Reserve seven years ago. Dr. Tilton serves as Director of Immunobiology of the CWRU Center for Proteomics and Bioinformatics and holds a secondary appointment in the Department of Molecular Biology and Microbiology. Chip received his BA in Molecular Biology from Princeton University in 1995 and an MD from Yale University in 2001.



**Paul Tesar, Associate Professor, Genetics and Genome Sciences**

Dr. Paul Tesar is currently an Associate Professor and the Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics at CWRU School of Medicine in the Department of Genetics and Genome Sciences. Dr. Tesar earned his BS from Case Western Reserve University, then went on to earn his DPhil (PhD) from the University of Oxford as a recipient of a prestigious scholarship from the National Institutes of Health. His graduate studies under the tutelage of Professor Sir Richard Gardner and Dr. Ron McKay culminated in a landmark paper in Nature describing the discovery of a new type of pluripotent stem cell, epiblast stem cells. This work earned Dr. Tesar some of the highest graduate student accolades including the Beddington Medal from the British Society for Developmental Biology and the Harold M. Weintraub Award from Fred Hutchinson Cancer Research Center. Dr. Tesar returned home to join the CWRU School of Medicine faculty in 2010 as a Mt. Sinai Health Care Foundation Scholar, and has since been named a Robertson Investigator of the New York Stem Cell Foundation in 2011, received the International Society for Stem Cell Research Outstanding Young Investigator Award in 2015, the New York Stem Foundation - Robertson Stem Cell Prize in 2017, and the Diekhoff Award for Graduate Student Mentoring in 2018.



**CWRU Staff**

**Anne DeChant, Assistant Director, Translation and Innovation**

Ms. Anne DeChant, MS, MBA, is Assistant Director, Office of Translation and Innovation, School of Medicine, Case Western Reserve University. She has worked at the SOM for over 16 years and currently serves as a member of the Office of the Vice-Dean for Research and the Clinical and Translational Science Collaborative. Anne received a BS in Biology from The Ohio State University, a MS in Cell and Molecular Biology from Cleveland State University and an MBA from Case Western Reserve University Weatherhead School of Management.



**Daria Fedyukina, Translational Officer**

Dr. Daria Fedyukina works as a business analyst and translational officer at the CWRU School of medicine. Previously, Dr. Fedyukina spent many years in management and consulting with RegenxBio, L.E.K. Consulting, and LG Chem, in areas of commercialization, portfolio planning, business development, and life sciences strategy consulting. Dr. Fedyukina received her PhD from the University of Wisconsin.



**Bill Harte, Chief Translational Officer**

Dr. Bill Harte is a pharmaceutical executive with more than 25 years of experience in pharmaceutical/biotech research. Dr. Harte currently serves as the Chief Translational Officer at Case Western Reserve University, managing more than 20 translational research programs and supporting the School of Medicine's innovation pipeline. Dr. Harte previously co-founded E3x Bio, served as CEO of Visum Therapeutics, and spent years in pharma at Amgen and Bristol-Myers Squibb. Dr. Harte received a BS in Chemistry from Carnegie Mellon University and his PhD in Chemistry from Wesleyan University.



**Steve Fening, Director, Case-Coulter Translational Research Partnership**

Dr. Stephen Fening is the Director of the Case-Coulter Translational Research Partnership (CCTRP) in the Department of Biomedical Engineering at Case Western Reserve University. He received undergraduate and master's degrees in mechanical engineering, and a PhD in biomedical engineering. Dr. Fening is a co-founder and Chief Technology Officer of Apto Orthopaedics Corporation. He also has served on the board of directors for several for- and not-for-profits. Dr. Fening previously served as Director of Orthopaedic Devices at the Austen BioInnovation Institute in Akron and the Director of Orthopaedic Research for Summa Health Systems.



**Michael Haag, Executive Director, Technology Management**

Mr. Michael Haag, MS, MBA is the Executive Director of Technology Management at Case Western Reserve University. Mr. Haag is responsible for all intellectual property services at the university. Mr. Haag also serves as the managing director of CWRU Technology Ventures, and as president and CEO of ReXceptor, Inc. Mr. Haag received his BS in biology and chemistry from John Carroll University, his MS in biology from Case Western Reserve University, and his MBA from University of Phoenix.



**Carol Moss, Vice President for Health Sciences Development, Vice President for Medical External Affairs**

Ms. Carol Moss, MBA leads development efforts at the CWRU School of Medicine in her dual role as vice president for health sciences development, and vice president for medical external affairs. Ms. Moss previously served as vice chancellor for development and alumni relations at UCSF and chair of the division of institutional relations and development at Cleveland Clinic. Ms. Moss also serves on the board of directors of The First Tee Cleveland.



**Stacy Langenderfer, Senior Director of Development, Basic and Translational Sciences**

Ms. Stacy Langenderfer serves as the basic and translational sciences senior director of development for the CWRU School of Medicine. Ms. Langenderfer has over 10 years of experience in the health care industry, including previous work at University Hospitals of Cleveland and Pfizer.



**Rebecca Mason, Executive Director for Development Programs**

Ms. Rebecca Mason works in the Office of Development, currently serving as the Executive Director for Development Programs. Ms. Mason brings over 20 years of experience in communications and development from around the globe.

